Registries as a tool in evidence-based medicine: Example of KIMS (Pfizer International Metabolic Database)

Pharmacoepidemiology and Drug Safety

Volumn 17, Issue 1, 2008, Pages 90-102

  Gutiérrez, Lia P ^a   Kołtowska Häggström, Maria ^a,b   Jönsson, Peter J ^a   Mattsson, Anders F ^a   Svensson, Dag ^a   Westberg, Björn ^a   Luger, Anton ^c  

^a PFIZER INC   (United States)

^b UPPSALA UNIVERSITY   (Sweden)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Growth hormone deficiency in adults; Hypopituitarism; Pharmacoepidemiology; Safety; Survey; Treatment outcome

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; GLUCOCORTICOID; GROWTH HORMONE; HUMAN GROWTH HORMONE; SEX HORMONE; THYROID HORMONE; VASOPRESSIN;

ADRENAL INSUFFICIENCY; ADULT; ARTHRALGIA; ARTICLE; BACKACHE; BODY COMPOSITION; BRAIN CANCER; BREAST CANCER; CARDIOVASCULAR RISK; CENTRAL NERVOUS SYSTEM TUMOR; CEREBROVASCULAR DISEASE; CITATION ANALYSIS; CLINICAL FEATURE; CONTROLLED STUDY; DATA ANALYSIS; DEPRESSION; DOSE RESPONSE; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; FEMALE; FLU LIKE SYNDROME; GENERALIZED EDEMA; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HYPOPHYSIS TUMOR; HYPOPITUITARISM; LIPID COMPOSITION; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL LITERATURE; MELANOMA; METHODOLOGY; OUTCOMES RESEARCH; PHARMACOEPIDEMIOLOGY; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; QUALITATIVE RESEARCH; QUALITY OF LIFE; REGISTER; SKIN CARCINOMA; UPPER RESPIRATORY TRACT INFECTION;

ADULT; BODY COMPOSITION; CHOLESTEROL; EVIDENCE-BASED MEDICINE; FEMALE; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; HYPOPITUITARISM; MALE; PROSPECTIVE STUDIES; QUALITY OF LIFE; RECOMBINANT PROTEINS; REGISTRIES; TREATMENT OUTCOME;

EID: 38849127612     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1510     Document Type: Article

References (33)

1. International Society for Pharmacoepidemiology (ISPE). Statement on Regulatory Systems to Improve Pharmaceutical Safety. http://www.pharmacoepi.org/resources/regstatement0205.pdf
2. Altman DG. What randomized trials and systematic reviews can offer decision makers. Horm Res 1999; 51(Suppl 1): 36-43.
3. Franciosa JA. The potential role of community-based registries to complement the limited applicability of clinical trial results to the community setting: heart failure as an example. Am J Manag Care 2004; 10: 487-492.
4. Haenszel W, Curnen MG. The first fifty years of the Connecticut tumour registry: reminiscences and prospects. Yale J Biol Med 1986; 59: 475-484.
5. Tunstall-Pedoe H, Kuulasmaa K, Mähönen M, et al. Contribution of trends in survival and coronary-event rates to changes in coronary Herat disease mortality - 10 year results from 37 WHO MONICA project populations: monitoring trends and determinants of cardiovascular disease. Lancet 1999; 353: 1547-1557.
6. Buehler JW. Surveillance. In Modern Epidemiology (2nd edn), Rothman KJ, Greenland S (eds). Lippincott Williams & Wilkins: Philadelphia, 450.
7. Monson J, Mussey S. Topical Briefings. Adult growth hormone (GH) replacement (the use of Somatotrophin [GH] in the management of adult Somatotrophin deficiency). Bristol, The Society for Endocrinology, 2004.
8. Leal Cerro A. Long-term challenges in growth hormone treatment. Horm Res 2004; 62(Suppl 4): 23-30.
9. Rosen T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990; 336: 285-288.
10. McCallum RW, Petrie JR, Dominiczak AF, Connell JM. Growth hormone deficiency and vascular risk. Clin Endocrinol 2OO2; 57: 11-24.
11. Verbelst J, Abs R. Long-term growth hormone replacement therapy in hypopituitary adults. Drugs 2002; 62: 2399-2412.
12. Simpson H, Savine R, Sönsksen P, et al. Growth hormone replacement therapy for adults: into the new millennium. Growth Horm IGF Res 2002; 12: 1-33.
13. Riis P. Thirty years of bioethics: the Helsinki Declaration 1964-2003. New Rev Bioeth 2003; 1: 15-25.
14. Abs R. Feldt-Rasmussen U (eds). Growth hormone deficiency in adults. 10 years of KIMS. Oxford PharmaGenesis™ Ltd.: Oxford, UK, 2004; 346-348.
15. Friedewald WT Levy RI, Fredickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
16. McKenna SP, Doward LC, Alonso J, et al. The QoL-AGHDA: an instrument for the assessment of quality of life in adults with growth hormone deficiency. Quality of life Res 1999; 8: 373-383.
17. Koltowska-Häggström M, Mattsson AF, Monson JP, et al. Does long-term growth hormone replacement therapy in hipopituitary adults with growth hormone deficiency normalize quality of life? Eur J Endocrinol 2006; 155: 109-119.
18. International Monitoring of Adverse Reactions to Drugs. WHO Adverse Reaction Terminology, 31 December 2003. The Uppsala Monitoring Center, Uppsala, Sweden.
19. Abs R, Bengtsson BA, Hemberg-Ståhl, et al. GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety. Clin Endocrinol 1999; 50: 703-713.
20. Abs R, Mattsson AF, Bengtsson BA, et al. Isolated growth hormone (GH) deficiency in adult patients: baseline clinical characteristics and responses to GH replacement in comparison with hypopituitary patients. A, sub-analysis of the KIMS database. Growth Horm IGF Res 2005; 15: 349-359.
21. Verhelst J, Kendall-Taylor P, Erfurth EM, et al. Baseline characteristics and response to 2 years of growth hormone (GH) replacement of hypopituitary patients with GH deficiency due to adult-onset craniopharyngioma in comparison with patients with nonfunctioning pituitary adenoma: data from KIMS (Pfizer International Metabolic Database). J Clin Endocrinol Metab 2005; 90: 4636-4643.
22. Kendall-Taylor P, Jönsson PJ, Abs R, et al. The clinical, metabolic and endocrine features and the quality of life in adults with childhood-onset craniopharyngioma compared with adult-onset craniopharyngioma. Eur J Endocrinol 2005; 152: 557-567.
23. Maiter D, Abs R, Johansson G, et al. Baseline characteristics and response to GH replacement of hypopituitary patients previously irradiated for pituitary adenoma or craniopharyngioma: data from the Pfizer International Metabolic Database. Eur J Endocrinol 2006; 155: 253-260.
24. Abs R, Feldt-Rasmussen U, Mattsson AF, et al. Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults - a KIMS database analysis. Eur J Endocrinol 2006; 155: 79-90.
25. Bengtsson BA, Koppeschaar HPF, Abs R, et al. Growth hormone replacement therapy is not associated with any increase in mortality. KIMS Study Group. J Clin Endocrinol Metab 1999; 84: 4291-4292.
26. Monson JP. Long-term experience with GH replacement therapy: efficacy and safety. Eur J Endocrinol 2003; 148 (Suppl 2): S9-14.
27. Keleştimur F, Jonsson P, Molvalilar S, et al. Sheehan's syndrome: baseline characteristics and effects of 2 years of growth hormone replacement therapy in 91 patients in KIMS - Pfizer International Metabolic Database. European Journal of Endocrinology 2005; 152: 581-587.
28. Feldt-Rasmussen U, Abs R, Bengtsson B-Å, et al. Growth hormone deficiency and replacement in hypopituitary patients previously treated for acromegaly and Cushing's. European Journal of Endocrinology 2002; 146: 67-74.
29. Monson JP, Abs R, Bengtsson B-Å, et al. Growth hormone deficiency and replacement in elderly hypopituitary adults. Clin Endocrinol 2000; 53: 281-289.
30. Mah PM, Webster J, Jönsson P, Feldt-Rasmussen U, Koltowska-Häggström M, Ross RJM. Oestrogen replacement in hypopituitary women of fertile years. J Clin Endocrinol Metab 2005; 90: 5964-5969.
31. Lisett C, Jonsson P, Monson JP. Shalet SM Determinants of IGF-I status in a large cohort of growth-hormone deficient (GHD) subjects: the role of timing of onset of GHD. Clin Endocrinol 2003; 59: 773-778.
32. Mukherjee A, Monson JP, Jonsson PJ, Trainer PJ, Shalet S. Seeking the optimal target range for insulin-like growth factor I during the treatment of adult growth hormone disorders. J Clin Endocrinol Metab 2003; 88(12): 5865-5870.
33. National Institute for Clinical Excellence (NICE). Technology Appraisal 64: Human Growth Hormone (Somatotropin) in Adults with Growth Hormone Deficiency. NICE, 2003.